Inquiry Contact

Home
Who we are
Why Choose Us
Botanical Extracts

Phytochemicals

Cosmoceuticals

Oleoresins
Other Health Ingredients
Therapeutic Applications
Premixes & Formulas
Consulting & Contract Research
Exhibitions
Testimonials

 

 

LYBERGIC SPECIALITY INGREDIENTS
  Potent H-1 Antagonist for Allergies  
RESEARCH STATUS
Clinical data Pending
Preclinical data Available
Short term Toxicity data Available
Long term Toxicity date Pending
Phytochemical standardization Pending











Many a times Allergens present in the environment tigger various allergic reactions. One of the most fatal is Asthma. Nearly four out of ten childern suffer from asthma and the risk factor related to this diseases is increases day by day. Allergens causes the lining of the airways to become swollen and inflamed. It produces extra mucus and the muscle of the airways tighten due to which there is less room left for the air to pass in and out which leads to breathlessness.

The growing environmental pollution with rapid and extensive industrialization is also responsible for aggravation of this disease. The alarming rise in the incidence of this disease in metropolitan cities has posed a serious problem.

Lybergic is derived from the bark of large deciduous tree commonly occurring in the Himalayas. Lybergic showed significant protection against histamine induced respiratory challenge in Guinea pigs.

Dosage / Suggested Use: 1 capsule tid

PHARMACOLOGICAL EFFECTS OF LYBERGIC

Model Dose Results
Antiasthama activity against histamine induced bronchspasm in guinea pigs. Lybergic (100 mg/kg b.w & 200 mg/kg b.w) Chlorpheneramine maleate (4.5 mg/kg po) Lybergic was able to give protection from histamine challenge to the extent of 75% and 87.5% at 100 mg/kg and 200 mg/kg doses.
Passive paw anaphylaxis model in rats. Lybergic (100 mg/kg b.w and 200 mg/kg b.w)
Dexamethasone as a reference standard
(1 mg/kg of body weight)
Lybergic at the dose of 100 and 200 mg/kg demonstrated significant (P<0.05) decrease in the rat paw edema to the extent of 33.09% and 42.48 % respectively.

SAFETY
Acute Oral Toxicity study
The LD50 established at > 2 gm/kg

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, cure, treat or prevent any disease.
 
<< BACK     

Copyright 2004, All Rights Reserved